DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

Bibliographic Details
Main Authors:	Morgan C, Jin X, Yu X, De Rosa S, Kublin J, Metch B, Keefer M, NIAID H
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
by: Yunda Huang, et al.
Published: (2015-01-01)

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans?
by: Albert J, et al.
Published: (2006-12-01)

P14-02. Social impact events in Phambili, the first phase 2B HIV vaccine trial in South Africa
by: Roux S, et al.
Published: (2009-10-01)

Safety and immunogenicity of an HIV adenoviral vector boost after DNA plasmid vaccine prime by route of administration: a randomized clinical trial.
by: Beryl A Koblin, et al.
Published: (2011-01-01)

Gender Mainstreaming in HIV Vaccine Trials in India
by: Singh Meeta
Published: (2005-12-01)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
by: Zoe Moodie, et al.
Published: (2020-05-01)

Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models
by: Dobromir Dimitrov, et al.
Published: (2015-12-01)

Gender aspects on HIV prevention efforts and participation in HIV vaccine trials among Police officers in Dar es Salaam, Tanzania
by: Edith A. M. Tarimo, et al.
Published: (2018-07-01)

Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
by: Koblin B, et al.
Published: (2012-09-01)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
by: Zanele Ditse, et al.
Published: (2020-02-01)

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination.
by: Jacob A Cram, et al.
Published: (2019-01-01)

New HIV peptide-based immunoassay resolves vaccine-induced seropositivity in HIV vaccine (Phase III) trial participants
by: Penezina O, et al.
Published: (2012-09-01)

House Ball Community Leaders’ Perceptions of HIV and HIV Vaccine Research
by: Amina P. Alio, PhD, et al.
Published: (2020-02-01)

HIV vaccines.
by: Mcmichael, A
Published: (2006)

Attracting, equipping and retaining young medical doctors in HIV vaccine science in South Africa
by: Danna Flood, et al.
Published: (2015-11-01)

Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China.
by: Yuan Dong, et al.
Published: (2014-01-01)

Plasmids for therapy and vaccination /
by: Schleef, M. (Martin)
Published: (2001)

Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya.
by: Borna A Nyaoke, et al.
Published: (2017-01-01)

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.
by: Marnie L Elizaga, et al.
Published: (2018-01-01)

Future vaccines for HIV.
by: Blanchard, T, et al.
Published: (1996)

Is an HIV vaccine possible?
by: Mcmichael, A, et al.
Published: (1999)

Is an HIV vaccine possible?
by: Nancy A. Wilson, et al.

HIV prevention by vaccine
by: Gallo Robert
Published: (2012-05-01)

Correction: Modeling HIV Vaccines in Brazil: Assessing the Impact of a Future HIV Vaccine on Reducing New Infections, Mortality and Number of People Receiving ARV
Published: (2010-01-01)

Correction: Modeling HIV Vaccines in Brazil: Assessing the Impact of a Future HIV Vaccine on Reducing New Infections, Mortality and Number of People Receiving ARV.
by: Maria Goretti P. Fonseca, et al.
Published: (2010-01-01)

Sequence and vector shapes vaccine induced antibody effector functions in HIV vaccine trials.
by: Stephanie Fischinger, et al.
Published: (2021-11-01)

Willingness to Participate in HIV Vaccine Trials Among Young Nale Nigerian Traders
by: Onigbogi Olanrewaju
Published: (2005-12-01)

Correction to: Under consent: participation of people with HIV in an Ebola vaccine trial in Canada
by: Pierre-Marie David, et al.
Published: (2021-06-01)

44 Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya
by: B.A. Nyaoke, et al.
Published: (2016-07-01)

Vaccine: From Conventional To Plasmid Dna Borne Vaccine
by: Perpustakaan UGM, i-lib
Published: (2005)

Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.
by: Roland R Regoes, et al.
Published: (2005-08-01)

Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.
Published: (2005-08-01)

HIV vaccines 1983-2003.
by: Mcmichael, A, et al.
Published: (2003)

Design and tests of an HIV vaccine.
by: McMichael, A, et al.
Published: (2002)

HIV: vaccines out of Africa.
by: Rowland-Jones, S
Published: (2001)

What is required of an HIV vaccine?
by: Bangham, C, et al.
Published: (1997)

An HIV vaccine: how and when?
by: Esparza José
Published: (2001-01-01)

An HIV vaccine: how and when?
by: José Esparza

HIV: the pursuit of an elusive vaccine
by: Annie Coulson
Published: (2023-08-01)

Major HIV vaccine candidates
by: Wojciech Zdziennicki, et al.
Published: (2023-05-01)